Liver transplantation outcomes have significantly improved for patients with hepatitis B

August 09, 2004

Since the early 1990s, therapeutic options for patients undergoing liver transplantation for hepatitis B have evolved to include HBV immune globulin (HBIG) and lamivudine. At the same time, the outcomes for liver transplant recipients with hepatitis B improved dramatically, as detailed in a new study published in the August 2004 issue of Liver Transplantation, the official journal of the American Association for the Study of Liver Diseases (AASLD) and the International Liver Transplantation Society (ILTS).

Liver Transplantation is published on behalf of the societies by John Wiley & Sons, Inc., and is available online via Wiley InterScience at

Before the arrival of HBIG and lamivudine, people with hepatitis B were poor candidates for liver transplantation, because the virus almost always infected and destroyed their new organ. Then therapeutic innovations arrived. In the early 1990s in the United States, HBIG became widely used after being shown to significantly reduce the incidence of recurrent hepatitis B. In 1995, lamivudine was found to be effective against hepatitis B. Most recently, new antiviral agents like adefovir may help patients whose hepatitis B is resistant to other therapies.

In light of these innovations, researchers, led by W. Ray Kim, M.D., of the Mayo Clinic, examined 15 years of data on outcomes after liver transplantation for recipients with hepatitis B-related liver disease. The researchers hypothesized that these patients' survival would have improved over time, more than that of transplant recipients with other diagnoses, likely due to the therapeutic advances.

The researchers used data from the United Network for Organ Sharing (UNOS) for all adults receiving transplants between 1987 and 2002. They divided the data into three time frames: Era 1(1987-1991) when no prophylaxis was routinely used; Era 2 (1992-1996) when HBIG was used alone; and Era 3 (1997-2002) when both HBIG and lamivudine were used together. They collected information on each patient's diagnosis and survival after transplant and used statistical analyses to compare survival between groups. They also analyzed demographic and other data such as age, race and ischemic times.

As the eras progressed, the 5-year-survival for patients with hepatitis B improved impressively, from 53 percent to 69 percent to 76 percent. At the same time, liver transplant recipients with hepatitis B went from having significantly lower survival rates than those with other diagnoses, to having comparable, if not higher, survival rates.

"These continual improvements suggest that advances in the prevention and treatment of recurrent HBV disease have been adopted in a timely and widespread fashion," report the authors.

Due to a lack of available data on post-transplant patient management, histology, and prophylactic regimen, the researchers were not able to directly correlate the outcome improvements with therapeutic innovations. Still, they report that the outcome of liver transplantation for patients with hepatitis B has improved significantly over the past 17 years, commensurate with therapeutic innovations introduced during the same period.

"These data underscore the importance of therapeutic innovations that have occurred incrementally in the past two decades for hepatitis B and support liver transplantation as an appropriate treatment for patients with acute and chronic insufficiency or HCC from HBV," the authors conclude.
Article: "Outcome of Liver Transplantation for Hepatitis B in the United States." W. Ray Kim, John J. Poterucha, Walter K. Kremers, Michael B. Ishitani, and E. Rolland Dickson; Liver Transplantation; August 2004; 10:8; pp. 968-974.


Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to